engleski

The treatment of severe refractory atopic dermatitis with new oral formulation of cyclosporin

A new microemulsified formulation fo cyclosporin, appears to be at least as effective as the traditional formulation of cyclosporin in treatment of severe atopic dermatitis and psoriasis. Side effects are similar to those seen with the traditional formulation. Aim of the study was to demonstrate response to the severe atopc dermatitis (AD) were treated with new formulation of cyclosporin 5 mg/kg/day until 8 weeks of treatment. Ten patients were in remission after 6 weeks, or for a maximun of 8 weeks, and five subject had mild skin changes after 8 weeks of treatemtent. Side effects were not seen. Considered overall tolerability good or excellent. No sustained rise in blood pressure or serum creatinine occurred. Relapse, defined as a need for futher treatement, occured in 3 cases between 4 and 6 weeks afer stopping treatment. An equally pleasing response has been seen in the treatment of 14 months old child refractory atopic dermatitis. Quality of life is also markedly improved. The present results suggest that this formulation of cyclosporin is useful in eight weeks management of severe, refractory atopic dermatitis (baseline SCORAD score reduction)

atopic dermatitis; cyclosporin

nije evidentirano